Table 1.

Associations of melanoma susceptibility variants, genes, and pathways with pancreatic cancer risk

PanScan IPanScan IICombined PanScan I and IIMayo clinic combined subset
ChromosomeSNPGene regionMelanoma OR (95% CI)Minor/ref. alleles, MAFaOR (95% CI)POR (95% CI)POR (95% CI)POR (95% CI)P
Susceptibility variants observed in GWAS
1rs3219090PARP10.91 (0.85–0.97)T/C 0.350.94 (0.85–1.03)0.201.02 (0.91–1.14)0.760.98 (0.91–1.05)0.521.17 (0.99–1.38)0.07
1rs7412746ARNT/CYCSP510.89 (0.85–0.95)C/T 0.470.98 (0.89–1.08)0.661.03 (0.93–1.15)0.541.02 (0.95–1.09)0.660.94 (0.80–1.10)0.43
2rs13016963ALS2CR121.11 (1.06–1.18)A/G 0.401.07 (0.97–1.18)0.161.01 (0.91–1.13)0.871.05 (0.98–1.13)0.201.007 (0.85–1.19)0.94
9rs10757257MTAP0.83 (0.76–0.91)A/G 0.391.04 (0.94–1.14)0.451.06 (0.96–1.18)0.251.05 (0.97–1.12)0.211.03 (0.88–1.22)0.69
9rs1335510Near MTAP0.84 (0.77–0.92)G/T 0.391.05 (0.96–1.16)0.301.05 (0.95–1.17)0.351.05 (0.98–1.12)0.201.08 (0.91–1.27)0.37
9rs1408799Near TYRP10.87 (0.81–0.94)T/C 0.341.05 (0.95–1.16)0.361.08 (0.97–1.21)0.181.08 (0.998–1.16)0.060.98 (0.82–1.17)0.78
9rs2218220Near MTAP1,15 (1.09–1.22)C/T 0.510.99 (0.91–1.09)0.850.95 (0.86–1.06)0.350.97 (0.91–1.04)0.470.96 (0.82–1.13)0.62
9rs7023329MTAP0.85 (0.80–0.91)G/A 0.471.02 (0.93–1.12)0.721.06 (0.95–1.17)0.301.03 (0.96–1.11)0.361.05 (0.89–1.23)0.58
10rs17119434Near YWHAZP56.8 (3.3–14.2)G/A 0.011.04 (0.67–1.62)0.860.97 (0.59–1.60)0.901.05 (0.76–1.45)0.782.12 (0.91–5.03)0.08
10rs17119461Near YWHAZP58.4 (4.2–17.0)C/T 0.010.99 (0.63–1.55)0.961.03 (0.63–1.70)0.901.05 (0.75–1.46)0.782.62 (1.08–6.35)0.03
10rs17119490Near YWHAZP58.4 (4.2–17.0)A/G 0.011.02 (0.65–1.59)0.951.04 (0.63–1.72)0.871.07 (0.77–1.49)0.692.62 (1.08–6.34)0.03
11rs1042602TYR0.92 (0.87–0.98)A/C 0.371.03 (0.94–1.14)0.531.03 (0.93–1.15)0.551.04 (0.97–1.12)0.280.97 (0.82–1.14)0.71
11rs1393350TYR1.29 (1.21–1.38)A/G 0.231.11 (0.99–1.23)0.080.92 (0.81–1.03)0.161.008 (0.93–1.09)0.851.008 (0.83–1.22)0.94
11rs1801516ATM0.87 (0.81–0.94)A/G 0.161.02 (0.89–1.16)0.810.95 (0.82–1.10)0.500.99 (0.90–1.09)0.861.15 (0.92–1.44)0.21
11rs1806319TYR/NOX41.24 (1.13–1.35)C/T 0.351.07 (0.97–1.18)0.190.90 (0.80–1.00)0.060.98 (0.92–1.06)0.680.99 (0.83–1.17)0.88
16rs258322CDK101.67 (1.52–1.83)A/G 0.270.94 (0.81–1.10)0.461.02 (0.85–1.23)0.820.98 (0.87–1.10)0.701.01 (0.78–1.33)0.92
16rs4785763AFG3L11.36 (1.28–1.45)A/C 0.291.07 (0.97–1.19)0.160.98 (0.87–1.09)0.671.03 (0.95–1.11)0.491.12 (0.94–1.34)0.19
20rs1015362RPS2P1/XPOTP10.69 (0.61–0.78)T/C 0.280.99 (0.89–1.10)0.781,08 (0.96–1.21)0.211.02 (0.95–1.11)0.561.04 (0.87–1.24)0.66
20rs4911414RPS2P1/XPOTP11.45 (1.29–1.64)T/G 0.311.01 (0.92–1.12)0.831.09 (0.97–1.22)0.151.03 (0.96–1.11)0.441.14 (0.96–1.35)0.13
20rs4911442NCOA61.51 (1.33–1.7)G/A 0.091.04 (0.84–1.20)0.650.997 (0.85–1.17)0.970.998 (0.90–1.11)0.971.32 (1.03–1.70)0.03
21rs45430MX20.91 (0.86–0.96)C/T 0.370.98 (0.89–1.08)0.670.99 (0.89–1.11)0.880.99 (0.92–1.07)0.800.98 (0.83–1.16)0.85
22rs2284063PLA2G60.83 (0.78–0.88)G/A 0.340.93 (0.85–1.03)0.151.04 (0.93–1.16)0.480.98 (0.91–1.05)0.601.02 (0.86–1.20)0.86
22rs6001027PLA2G60.83 (0.78–0.89)G/A 0.340.93 (0.84–1.02)0.121.04 (0.93–1.16)0.530.98 (0.91–1.05)0.491.01 (0.85–1.20)0.90
SNPs in high LD (r2 > 0.5) with susceptibility variants of interest
9rs935053 [rs10965127, rs7040895]bNear MTAP0.81 (0.74–0.89)A/G 0.500.91 (0.78–1.07)0.250.95 (0.85–1.05)0.330.97 (0.91–1.04)0.410.93 (0.71–1.21)0.58
11rs10830253 [rs1393350, rs1939255]bTYR1.26 (1.14–1.39)G/T 0.301.11 (0.99–1.23)0.080.84 (0.66–1.06)0.140.90 (0.77–1.06)0.200.92 (0.65–1.30)0.64
11rs1847142 [rs1393350, rs1939255]bTYR1.31 (1.21–1.41)A/G 0.301.11 (0.99–1.23)0.080.84 (0.66–1.06)0.140.90 (0.77–1.06)0.200.92 (0.65–1.30)0.64
15rs12913832 [rs7183877]bHERC20.69 (0.61–0.79)A/G 0.291.13 (0.94–1.37)0.201.06 (0.87–1.28)0.581.11 (0.97–1.27)0.130.81 (0.57–1.15)0.24
20rs1885120 [rs11906160, rs6058154]bMYH7B1.78 (1.54–2.04)C/G 0.051.003 (0.91–1.10)0.950.97 (0.82–1.15)0.730.98 (0.88–1.10)0.761.09 (0.93–1.28)0.29
  • aMinor and reference alleles and minor allele frequency (MAF) in Europeans.

  • bVariant(s) within brackets are in LD with the targeted SNP and are used to represent the association between the targeted variant and pancreatic cancer risk.